Closing The Books On Aduhelm: Congressional Report Leaves US FDA To Move Forward

A Congressional report on the US FDA approval of Biogen/Eisai’s Aduhelm generated another round of negative headlines for the agency – and rubbed salt in the wounds of a commercial disaster for the sponsors. But it probably could not have turned out better for FDA and the drug review climate overall.

closing the book on Aduhelm
The House report on Aduhelm is probably headed straight for the shelf. • Source: Nielsen Hobbs; the Pink Sheet | Shutterstock, House report images

It is hard to imagine a quieter end to the House Energy & Commerce Committee’s investigation into the US Food & Drug Administration’s handling of the review of Biogen, Inc./Eisai Co., Ltd.’s Alzheimer’s therapy Aduhelm (aducanumab-avwa).

The Congressional inquiry was launched with much fanfare two weeks after Aduhelm was approved in June 2021, amid headlines warning...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Product Reviews

More from Pink Sheet

Recent And Upcoming FDA Advisory Committee Meetings

 
• By 

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK-Wide Strategy Needed To Move Clinical Trial Diversity Plans To Next Stage

 
• By 

The UK’s research-based pharma industry and medical research charities have set out clear action points to drive greater diversity and inclusion in clinical trials.

Blenrep’s Comeback Continues As England Becomes First To Fund Drug

 

Blenrep, GSK’s multiple myeloma therapy, faced a major setback when it was withdrawn from the market in 2022. The drug has since made a return as a second-line therapy, and is on track to being reimbursed in England.